程序性细胞死亡蛋白-1及其配体抑制剂在胆道肿瘤治疗中的现状与前景

Present situation and prospect of PD-1 / PD-L1 inhibitors in the treatment of biliary tract cancer

摘要: 胆道肿瘤是一种预后极差的疾病。目前，仅有小部分的早期患者可以接受根治性切除术，而传统放疗、化疗、靶向治疗等对胆道肿瘤作用有限。免疫系统在胆道肿瘤的发病机理中扮演重要角色。因此，以程序性细胞死亡蛋白-1及其配体(PD-1/PD-L1)抑制剂为代表的免疫检查点抑制剂在胆道肿瘤的治疗中具有巨大潜在价值。笔者分析国内外最新研究进展，结合自身治疗经验与当前临床热点问题，深入探讨PD-1/PD-L1抑制剂在胆道肿瘤治疗中的现状及前景。

Abstract: The biliary tract cancer (BTC) is a kind of disease with poor prognosis. Due to the lack of typical clinical manifestations and the effective early diagnosis method, the disease is usually detected at an advanced stage and lost the opportunity of surgical therapy. While the traditional radiotherapy and chemotherapy are limited in the treatment of BTC. The immune system plays an important role in the pathogenesis of BTC. Therefore, the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors may have great potential value in the treatment of BTC. Authors reviewed the latest literatures and tried to find the current situation and prospect of PD-1 / PD-L1 inhibitors in the treatment of BTC.